Rani Therapeutics reported positive initial Phase 1 data for RT-114, an orally administered RaniPill Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist. The update is an early clinical milestone supporting continued development progress for the program, with limited immediate quantification of efficacy/safety details provided in the report.
Rani Therapeutics reported positive initial Phase 1 data for RT-114, an orally administered RaniPill Capsule delivering PG-102, a GLP-1/GLP-2 dual agonist. The update is an early clinical milestone supporting continued development progress for the program, with limited immediate quantification of efficacy/safety details provided in the report.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
